Neurocysticercosis in sub-Saharan Africa: A review of prevalence, clinical characteristics, diagnosis, and management

Pathogens and Global Health

Volumn 106, Issue 5, 2012, Pages 261-274

  Winkler, Andrea Sylvia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cysticercosis; Epilepsy; Sub Saharan Africa

Indexed keywords

ALBENDAZOLE; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; PRAZIQUANTEL; VALPROIC ACID;

ACNE; AFRICA; AGGRESSION; AGITATION; ARTICLE; ATAXIA; CEREBELLUM ATROPHY; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIPLOPIA; DISEASE EXACERBATION; ELECTROENCEPHALOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FATIGUE; GINGIVA HYPERPLASIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERKINESIA; HYPONATREMIA; IMMUNOBLOTTING; LEUKOPENIA; LIVER FAILURE; LYMPHATIC FILARIASIS; MEGALOBLASTIC ANEMIA; MOTOR DYSFUNCTION; MUSCLE HYPOTONIA; NAUSEA; NEUROCYSTICERCOSIS; NEUROIMAGING; NYSTAGMUS; PREVALENCE; RASH; RESPIRATION DEPRESSION; SCHISTOSOMIASIS; SIDE EFFECT; SINGLE DRUG DOSE; TAENIA SOLIUM; TAENIASIS; TERATOGENICITY; TREMOR; VERTIGO; VITAMIN K DEFICIENCY; X RAY;

AFRICA SOUTH OF THE SAHARA; EPILEPSY; HUMANS; NEUROCYSTICERCOSIS; PREVALENCE;

EID: 84874901585     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773212Y.0000000047     Document Type: Article

References (109)

1. Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol. 2005;4:21-31.
2. Del Brutto OH. Helminthic infections of the central nervous system. In: Noseworthy JH, editor. Neurological therapeutic principles and practice. 2nd ed. Abingdon, Oxon: Informa Health Care; 2006. p. 1133-52.
3. Campbell CD, Farrell VJR. Brain scans, epilepsy and cerebral cysticercosis. S Afr Med J. 1987;72:885-6.
4. Bern C, Garcia HH, Evans C, Gonzalez AE, Verastegui M, Tsang VC, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis. 1999;29:1203-9.
5. Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology. 2002;59:1730-4.
6. Del Brutto OH, Santibáñez R, Hidrovo L, Rodríguez S, DìazCalderón E, Navas C, et al. Epilepsy and neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. Epilepsia. 2005;46:583-7.
7. Foyaca-Sibat H, Cowan LD, Carabin H, Targonska I, Anwary MA, Serrano-Ocaña G, et al. Accuracy of serological testing for the diagnosis of prevalent neurocysticercosis in outpatients with epilepsy, Eastern Cape Province, South Africa. PLoS Negl Trop Dis. 2009;3:e562.
8. Shasha W, Pammenter MD. Sero-epidemiological studies of cysticercosis in school children from two rural areas of Transkei, South Africa. Ann Trop Med Parasitol. 1991;85:349-35.
9. Thomson AJG. Neurocysticercosis - experience at the teaching hospitals of the University of Cape Town. S Afr Med J. 1993;83:332-4.
10. Grill J, Rakotomalala W, Andriantsimahavandy A, Boisier P, Guyon P, Roux J, et al. High prevalence of serological markers of cysticercosis among epileptic Malagasy children. Ann Trop Paediatr. 1996;16:185-191.
11. Mafojane NA, Appleton CC, Krecek RC, Michael LM, Willingham AL 3rd. The current status of neurocysticercosis in eastern and southern Africa. Acta Trop. 2003;87:25-33.
12. Gaffo AL, Guillen-Pinto D, Campos-Olazabal P, Burneo JG. Cysticercosis as the main cause of partial seizures in children in Peru. Rev Neurol. 2004;39:924-926.
13. Wallin M, Kurtzke J. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. 2004;63:1559-1564.
14. Willingham AL III, Harrison LJ, Févre EM, Parkhouse ME. Inaugural meeting of the Cysticercosis Working Group in Europe. Emerg Infect Dis. 2008;14:e2.
15. Del Brutto OH. A review of cases of human cysticercosis in Canada. Can J Neurol Sci. 2012;39:319-322.
16. Del Brutto OH. Neurocysticercosis among international travelers. J Travel Med. 2012;19:112-117.
17. Del Brutto OH. Neurocysticercosis in Western Europe: a reemerging disease? Acta Neurol Belg. Epub 2012 Apr 18.
18. Serpa JA, Yancey LS, White AC Jr. Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther. 2006;4:1051-1061.
19. Davis LE. Neurocysticercosis. In: Power C, Johnson RT, editors. Emerging neurological infections. Boca Raton: Taylor & Francis; 2005. p. 261-287.
20. Zoli A, Shey-Njila O, Assana E, Nguekam JP, Dorny P, Brandt J, et al. Regional status, epidemiology and impact of Taenia solium cysticercosis in western and central Africa. Acta Trop. 2003;87:35-42.
21. Sikasunge CS, Phiri IK, Phiri AM, Siziya S, Dorny P, Willingham III AL. Prevalence of Taenia solium porcine cysticercosis in the Eastern, Southern and Western provinces of Zambia. Vet J. 2008;176:240-424.
22. Winkler AS, Willingham AL, Sikasunge CS, Schmutzhard E. Epilepsy and neurocysticercosis in sub-Saharan Africa. Wien Klin Wochenschr. 2009;12 1 Suppl 3: 3-12.
23. Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, et al. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis. 2010;4:e870.
24. World Bank 2011 [cited 2012 Aug]. Available from: http:// data.worldbank.org/sites/default/files/adi_2011-web.pdf
25. Edwards T, Scott AG, Munyoki G, Odera V, Chengo E, Bauni E, et al. Active convulsive epilepsy in a rural district of Kenya: a study of prevalence and possible risk factors. Lancet Neurol. 2008;7:50-56.
26. Winkler AS, Kerschbaumsteiner K, Stelzhammer B, Meindl M, Kaaya J, Schmutzhard E. Prevalence, incidence and clinical characteristics of epilepsy - a community-based door-to-door study in northern Tanzania. Epilepsia. 2009;50:2310-3.
27. WHO 2010. Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases [cited 2012 Aug]. Available from: http:// whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf
28. World Atlas 2010 [cited 2012 Aug]. Available from: http:// www.worldatlas.com/aatlas/populations/ctypopls.htm
29. Carabin H, Ndimubanzi PC, Budke CM, Nguyen H, Qian Y, Cowan LD, et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis. 2011;5:e1152.
30. Sanchez AL, Lindback J, Schantz PM, Sone M, Sakai H, Medina MT, et al. A population based, case-control study of Taenia solium taeniasis and cysticercosis. Ann Trop Med Parasitol. 1999;93:247-258.
31. De Almeida SM, Torres LFB. Neurocysticercosis - retrospective study of autopsy reports, a 17-year experience. J Community Health. 2011;36:698-702.
32. Johnson RB. Potential hazard of mass praziquantel use. Am J Med. 1986;80:A88.
33. Torres JR, Noya O, de Noya BA, Mondolfi A. Seizures and praziquantel. A case report. Rev Inst Med Trop Sao Paulo. 1988;30:433-6.
34. Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, et al. Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel. The Lancet. 1993;342:748.
35. Garcia HH, Gonzalez I, Mija L. Neurocysticercosis uncovered by single-dose albendazole. N Engl J Med. 2007;356:1277-1278.
36. Sarti E, Schantz PM, Avila G, Ambrosio J, Medina-Santillán R, Flisser A. Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg. 2000;94:85-9.
37. World Health Organization. Weekly epidemiological record - Relevéé épidémiologique hebdomadaire No. 2, 2012, 87, 17-28 [cited 2012 Aug]. Available from: http://www.who.int/wer
38. Montano SM, Villaran MV, Ylquimiche L, Figueroa JJ, Rodriguez S, Bautista CT, et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology. 2005;65:229-33.
39. World Health Organization. Weekly epidemiological record Relevé épidémiologique hebdomadaire No. 35, 2011, 86, 377-37 8 [cited 2012 Aug]. Available from: http://www.who.int/wer
40. Zoli AP, Nguekam JP, Shey-Njila O, Nsame Nforninwe D, Speybroeck N, Ito A, et al. Neurocysticercosis and epilepsy in Cameroon. Trans R Soc Trop Med Hyg. 2003;97:683-686.
41. Quet F, Guerchet M, Pion SDS, Ngoungou EB, Nicoletti A, Preux PM. Meta-analysis of the association between cysticercosis and epilepsy in Africa. Epilepsia. 2010;51:830-837.
42. Winkler AS, Blocher J, Auer H, Gotwald T, Matuja W, Schmutzhard E. Epilepsy and neurocysticercosis in rural Tanzania - an imaging study. Epilepsia. 2009;50:987-993.
43. Del Brutto OH, Santibanez R, Noboa CA, Aguirre R, Diaz E, Alarcon TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992;42:389-392.
44. Takayanagui OM, Odashima NS. Clinical aspects of neurocysticercosis. Parasitol Int. 2006;55:S111-115.
45. Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol. 2011;7:584-594.
46. Callacondo D, Garcia HH, Gonzales I, Escalante D, Nash TE. Cysticercosis Working Group in Peru. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology. 2012;78:1394-400.
47. Nash TE, Del Brutto OH, Butman JA, Corona T, DelgadoEscueta A, Duron RM, et al. Calcific neurocysticercosis and epileptogenesis. Neurology. 2004;62:1934-8.
48. International League Against Epilepsy (ILAE). Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489-501.
49. International League Against Epilepsy (ILAE). Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30:389-99.
50. Birbeck GL. Revising and refining the epilepsy classification system: Priorities from a developing world perspective. Epilepsia. 2012;53 Suppl 2:18-21.
51. Winkler AS, Schaffert M, Schmutzhard E. Epilepsy in resource poor countries - suggestion of an adjusted classification. Epilepsia. 2007;48:1029-1030.
52. Winkler AS, Schaffert M, Schmutzhard E. The pattern of epilepsy in a rural African hospital - an approach adapted to local circumstances. Trop Doct. 2009;39:44-47.
53. Blocher J, Schmutzhard E, Wilkins PP, Gupton P, Schaffert M, Auer H, et al. A cross-sectional study of people with epilepsy and neurocysticercosis: clinical characteristics and diagnostic approaches. PLoS Negl Trop Dis. 2011;5:e1185.
54. Singh MK, Garg RK, Nath G, Verma DN, Misra S. Single small enhancing computed tomographic (CT) lesions in Indian patients with new-onset seizures: a prospective follow-up in 75 patients. Seizure. 2001;10:573-8.
55. Chandy MJ, Rajshekhar V, Ghosh S, Prakash S, Joseph T, Abraham J, et al. Single small enhancing CT lesions in Indian patients with epilepsy: clinical, radiological and pathological considerations. J Neurol Neurosurg Psychiatry. 1991;54:702-705.
56. Rajshekhar V, Joshi DD, Doanh NQ, van De N, Xiaonong Z. Taenia solium taeniosis/cysticercosis in Asia: epidemiology, impact and issues. Acta Trop. 2003;87:53-60.
57. Singh G, Rajshekhar V, Murthy JMK, S. Prabhakar, S. Modi, M. Khandelwal et al A diagnostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology. 2010;75:2236-45.
58. Singh G, Singh P, Singh I, Rani A, Kaushal S, Avasthi G. Epidemiologic classification of seizures associated with neurocysticercosis: observations from a sample of seizure disorders in neurologic care in India. Acta Neurol Scand. 2006;13:233-240.
59. Rosenfeld EA, Byrd SE, Shulman ST. Neurocysticercosis among children in Chicago. Clin Infect Dis. 1996;23:262-8.
60. García HH, Gonzalez AE, Rodriguez S, Tsang VC, Pretell EJ, Gonzales I, et al. Neurocysticercosis: unraveling the nature of the single cysticercal granuloma. Neurology. 2010;75:654-8.
61. Del Brutto OH, Nash TE, Garcia HH. Cysticerci-related single parenchymal brain enhancing lesions in non-endemic countries. J Neurol Sci. 2012;319:32-36.
62. Cruz ME, Schantz PM, Cruz I, Espinosa P, Preux PM, Cruz A, et al. Epilepsy and neurocysticercosis in an Andean community. Int J Epidemiol. 1999;28:799-803.
63. van As AD, Joubert J. Neurocysticercosis in 578 black epileptic patients. S Afr Med J. 1991;80:327-328.
64. Mason P, Houston S, Gwanzura L. Neurocysticercosis: experience with diagnosis by ELISA serology and computerised tomography in Zimbabwe. Cent Afr J Med. 1992;38:149-54.
65. Ky H, van Chap N. Radioclinical aspects of cerebral and muscular cysticercosis: 20 cases. J Neuroradiol. 2000;27:264-266. French.
66. Huang B, Li G, Jia F, Liu F, Ge L, Li W, et al. Determination of specific IgG4 for diagnosis and therapeutic evaluation of cerebral cysticercosis. Chin Med J. (Engl) 2002;115:580-583.
67. Yuan Z, Ren HJ, Ding YZ, Zhang JS, Wang WP, Wu XL, et al. Clinical study on the treatment of severe neurocysticercosis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2004;22:213-7.
68. Verma A, Prasad KN, Gupta RK, Singh AK, Nyati KK, Rizwan A, et al. Toll-Like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J Infect Dis. 2010;202:1219-1225.
69. Ito A, Yamasaki H, Nakao M, Sako Y, Okamoto M, Sato MO, et al. Multiple genotypes of Taenia solium - ramifications for diagnosis, treatment and control. Acta Trop. 2003;87:95-101.
70. Katabarwa M, Lakwo T, Habumogisha P, Richards F, Eberhard M. Could neurocysticercosis be the cause of 'onchocerciasis-associated' epileptic seizures? Am J Trop Med Hyg. 2008;78:400-401.
71. Grunitzky E, Balogou AK, M'Bella M, Belo M, Sadzo A, Bouteille B, et al. Cysticercosis in patients with neurologic diseases in hospital milieu in Lomé, Togo. Ann Med Interne (Paris). 1995;146:419-422. French.
72. Nakao M, Okamoto M, Sako Y, Yamasaki H, Nakaya K, Ito A. A phylogenetic hypothesis for the distribution of two genotypes of the pig tapeworm Taenia solium worldwide. Parasitology. 2002;124:657-662.
73. Campbell G, Garcia HH, Nakao M, Ito A, Craig PS. Genetic variation in Taenia solium. Parasitol Int. 2006;55 S121-126.
74. Dorny P, Brandt J, Zoli A, Geerts S. Immunodiagnostic tools for human and porcine cysticercosis. Acta Trop. 2003; 87: 79- 86.
75. Sotelo J, Del Brutto OH. Review of neurocysticercosis. Neurosurg Focus. 2002;12:e1.
76. Pal DK, Carpio A, Sander JWAS. Neurocysticercosis and epilepsy in developing countries. J Neurol Neurosurg Psychiatry. 2000;68:137-43.
77. Del Brutto OH, Rajshekhar V, White AC Jr, Tsang VC, Nash TE, Takayanagui OM, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001;57:177-83.
78. Del Brutto OH. Neurocysticercosis. Semin in Neurol. 2005;25:243-251.
79. Abraham R, Livramento JA, Leite CDA, Pardini AX, Vaz AJ, Machado Lidos R. Neurocysticercosis: relationship between Taenia antigen levels in CSF and MRI. Arq Neuropsiquiatr. 2010;68:7-11.
80. Almeida CR, Ojopi EP, Nunes CM, Machado LR, Takayanagui OM, Livramento JA, et al. Taenia solium DNA is present in cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatr Clin Neurosci. 2006;56:307-10.
81. Hernández M, Gonzalez LM, Fleury A, Saenz B, Parkhouse RM, Harrison LJ, et al. Neurocysticercosis: detection of Taenia solium DNA in human cerebrospinal fluid using a semi-nested PCR based on HDP2. Ann Trop Med Parasitol. 2008;102:317-23.
82. Gabriël S, Blocher J, Dorny P, Abatih E, Schmutzhard E, Ombay M, et al. Added value of antigen ELISA in the diagnosis of neurocysticercosis in resource poor settings. PLoS Negl Trop Dis. 2012 (in print).
83. Nash TE, Singh G, White AC, Rajshekhar V, Loeb JA, Proaño JV, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology. 2006;67:1120-7.
84. Del Brutto OH, Wadia NH, Dumas M, Cruz M, Tsang VCW, Schantz PM. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci. 1996;142:1-6.
85. Carpio A. Neuroimaging in Neurocysticercosis [cited 2012 Aug]. Available from: http://emedicine.medscape.com/article/ 1168784-differential
86. Nash TE, Mahanty S, Garcia HH; Cysticercosis Group in Peru. Corticosteroid use in neurocysticercosis. Expert Rev Neurother. 2011;11:1175-1183.
87. Corona T, Lugo R, Medina R, Sotelo J. Single-day praziquantel therapy for neurocysticercosis. N Engl J Med. 1996;334:125.
88. Pretell EJ, Garcia HH, Gilman RH, Saavedra H, Martinez M, The Cysticercosis Working Group in Peru. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg. 2001;103:175-177.
89. Nguekam JP, Zoli AP, Ongolo-Zogo P, Dorny P, Brandt J, Geerts S. Follow-up of neurocysticercosis patients after treatment using an antigen detection ELISA. Parasite. 2003;10:65-68.
90. Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004;350:249-258.
91. Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP. Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8-year randomized study. J Clin Neurosci. 2007;14:1172-1177.
92. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470-472.
93. Specchio LM, Beghi E. Should antiepileptic drugs be withdrawn in seizure-free patients? Epilepsia. 2008;49:455-463.
94. Lossius MI, Hessen E, Mowinckel P, Stavem K, Erikssen J, Gulbrandsen P, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). CNS Drugs. 2004;18:201-2012.
95. Birbeck GL. Barriers to care for patients with neurologic disease in rural Zambia. Arch Neurol. 2000;57:414-417.
96. Mbuba CK, Ngugi AK, Fegan G, Ibinda F, Muchohi SN, Nyundo C, et al. Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study. Lancet Neurol. 2012;11:688-696.
97. Winkler AS. Measuring the epilepsy treatment gap in sub Saharan Africa. Lancet Neurol. 2012;11:655-657.
98. Winkler AS, Mayer M, Schnaitmann S, Ombay M, Mathias B, Schmutzhard E, et al. Belief systems of epilepsy and attitudes towards people living with epilepsy in a rural community of northern Tanzania. Epilepsy Behav. 2010;19:596-601.
99. Winkler AS, Mayer M, Ombay M, Mathias B, Schmutzhard E, Jilek-Aall L. Attitudes towards African traditional medicine and Christian spiritual healing regarding treatment of epilepsy in a rural community of northern Tanzania. Afr J Trad CAM. 2010;7:162-170.
100. Birbeck G, Chomba E, Atadzhanov M, Mbewe W, Haworth A. The social and economic impact of epilepsy in Zambia: a cross-sectional study. Lancet Neurol. 2007;6:39-44.
101. Willingham AL 3rd, Engels D. Control of Taenia solium cysticercosis/taeniosis. Adv Parasitol. 2006;61:509-506.
102. Pondja A, Neves L, Mlangwa J, Afonso S, Fafetine J, Willingham AL 3rd, et al. Prevalence and risk factors of porcine cysticercosis in Angonia District, Mozambique. PLoS Negl Trop Dis. 2010;4:e594.
103. Pawlowski ZS. Control of neurocysticercosis by routine medical and veterinary services. Trans R Soc Trop Med Hyg. 2008;102:228-32.
104. Pawlowski ZS, Allan JC, Meinardi H. Control measures for taeniosis and cysticercosis. In: Murrell KD, editor. WHO/ FAO/OIE Guidelines for the Surveillance, Prevention and Control of Taeniosis/Cysticercosis. Paris: OIE; 2005. p. 73-99.
105. Pawlowski ZS, Allan J, Sarti E. Control of Taenia solium taeniasis/cysticercosis; from research towards implementation. Int J Parasitol. 2005;35:1221-1232.
106. Pawlowski ZS. Perspectives on the control of Taenia solium. Parasitol Today. 1990;6:371-373.
107. Pawlowski ZS. Role of chemotherapy of taeniasis in prevention of neurocysticercosis. Parasitol Int. 2006;55: S105-S109.
108. Lescano AG, Garcia HH, Gilman RH, Gavidia CM, Tsang VC, Rodriguez S, et al. Taenia solium cysticercosis hotspots surrounding tapeworm carriers: clustering on human seroprevalence but not on seizures. PLoS Negl Trop Dis. 2009;3:e371.
109. Gonzales AE, Garcia HH, Gilman RH, Gavidia CM, Tsang VC, Bernal T, et al. Effective, single-dose treatment of porcine cysticercosis with oxfendazole. Am J Trop Med Hyg. 1996;54:391-394.